Moderna, Inc. (NASDAQ:MRNA) Q4 2022 Earnings Call Transcript
Operator: Good morning. My name is Kevin and welcome to Moderna's Fourth Quarter 2022 Earnings Call. Please be advised this call is being recorded.
Moderna Inc. (MRNA)
Market is closed
News
- First
- << Previous
- 81 - 90
- Next >>
10 Most Promising Biotech Stocks According to Analysts
Last year was a period of transition for biotech firms.
What Makes Moderna (MRNA) an Attractive Investment?
ClearBridge Investments, an investment management company, released its “ClearBridge Select Strategy” fourth quarter 2022 investor letter. A copy of the same can be downloaded here.
12 Most Profitable Pharmaceutical Stocks Now
The pharmaceutical industry was the center of attention in 2020 and 2021 after the deadly coronavirus pandemic ravaged the globe and disrupted the way of living.
Hedge Fund and Insider Trading News: David Einhorn, Stan Druckenmiller, Ray Dalio, Paul Tudor Jones, George Soros, Modulo Capital, Altisource Portfolio Solutions S.A. (ASPS), Moderna, Inc. (MRNA), and More
David Einhorn, Founder and President of Greenlight Capital exited his stakes in Intel (INTC), Rivian Automotive (RIVN), and News Corp. (NWS) in Q4, according to the hedge fund’s 13-F filing.
5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
In this article, we will take a look at the 5 most undervalued biotech stocks to buy according to hedge funds.
Is Moderna (MRNA) a High Growth Stock?
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here.
15 Most Undervalued Quality Stocks To Buy According To Hedge Funds
In this article, we discuss 15 most undervalued quality stocks to buy according to hedge funds.
Hedge Fund and Insider Trading News: Anthony Scaramucci, Brummer & Partners, Elliott Management, Waratah Capital Advisors, Oasis Management, BancFirst Corp (BANF), Moderna, Inc. (MRNA), and More
Dai Nippon Printing Co. notched its biggest daily stock-price gain since 2008 after a report that activist investor Elliott Management Corp. is building a stake in the venerable Japanese company.
5 Cheap Biotech Stocks To Buy
Since the company's July 2021 IPO, CRISPR Therapeutics AG (NASDAQ:CRSP) shares have fallen by 44%.
- First
- << Previous
- 81 - 90
- Next >>
Billionaire Hedge Funds
